Lactoferrin-modified liposomes (LF-lipo) achieve active targeting via LRP-1, which is highly expressed across diverse tumor types, enabling highly selective tumor delivery and suitability for systemic administration to treat metastatic lesions. Here, LRP1 is linked to neoplasm.